Answer
The most frequently reported adverse reactions to ublituximab are infections (55.8%) and infusion-related reactions (45.3%).
Sources for this answer
- Briumvi 150 mg concentrate for solution for infusionNeuraxpharm UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 2Document updated
Sources checked